Trial Details 52 Total Sites

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.

New York City, New York
facility
Mount Sinai Medical Center
1 facility
Recruiting
San Diego, California
facility
VA San Diego Healthcare System
1 facility
Recruiting
Las Vegas, Nevada
facility
Comprehensive Cancer Centers of Nevada
facility
Optum Health Care
2 facilities
Recruiting
Sacramento, California
facility
UC Davis Comprehensive Cancer Center
1 facility
Recruiting
Kansas City, Missouri
facility
HCA Midwest Health
1 facility
Recruiting
St. Paul, Minnesota
facility
Minnesota Oncology Hematology
1 facility
Recruiting
St. Petersburg, Florida
facility
Florida Cancer Specialist, North Region
1 facility
Recruiting
Norfolk, Virginia
facility
Virginia Oncology Associates
1 facility
Recruiting
Tallahassee, Florida
facility
SCRI Florida Cancer Specialists PAN
1 facility
Recruiting
Springfield, Missouri
facility
Cox Health Systems
1 facility
Recruiting
Peoria, Illinois
facility
Illinois Cancer Care
1 facility
Recruiting
West Palm Beach, Florida
facility
Florida Cancer Specialists
1 facility
Recruiting